Pluristem to Present at FDA Symposium

Pluristem to Present at FDA Symposium

HAIFA, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that the company has been invited to present at the
U.S. Food & Drug Administration's (FDA) Medical Countermeasures initiative
(MCMi) which is sponsoring its 2nd annual Regulatory Science Symposium on May
29-31, 2013 at FDA headquarters in Silver Spring, Maryland.

The FDA's Office of Counterterrorism and Emerging Threats, Medical
Countermeasures Initiative, invited Pluristem to present at this symposium.
William R. Prather RPh, MD, Pluristem's Senior Vice President Corporate
Development, will present Pluristem's patented PLX (PLacental eXpanded) cell
technology and its potential use in the treatment of the complications arising
from the acute radiation syndrome (ARS). The data presented by Dr. Prather
include preliminary preclinical information on the radio-mitigating activity
of intramuscularly administered PLX-RAD cells generated in collaboration with
Professor Raphael Gorodetsky and his team at the Biotechnology and
Radiobiology Laboratory at the Sharett Institute of Oncology at Hadassah
Medical Center, Hadassit,Hadassah Medical Organization (HMO), Jerusalem, the
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD,
and the Berlin Bradenburg Center for Regenerative Therapies (BCRT), Charite
University, Berlin. 

Zami Aberman, Pluristem's Chairman and CEO, stated, "We are proud to be
invited to present data on the use of our PLX cells to mitigate the harmful
effects sustained from acute radiation injury. This presentation is a
supplement to the work currently being performed by the National Institute of
Allergy and Infectious Diseases (NIAID), a part of the U.S. National
Institutes of Health (NIH), to evaluate our PLX cells in animal models of
ARS."

About Acute Radiation Syndrome (ARS)

ARS represents a constellation of signs and symptoms that occur between
several minutes and several weeks after exposure to high doses of ionizing
radiation and affecting multiple organs such as the hematological and
gastrointestinal systems. The hematological syndrome follows radiation damage
to the bone marrow and is characterized by severe decreases in red blood
cells, white blood cells and platelets that predispose afflicted individuals
to infection, bleeding and potential death.

The gastrointestinal syndrome follows radiation damage to the gastrointestinal
tract that can result in diarrhea, dehydration, electrolyte imbalance and
infection that can lead to death.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss that the use
of PLX cells could potentially mitigate the harmful effects sustained from
acute radiation injury we are using forward-looking statements. These
forward-looking statements and their implications are based on the current
expectations of the management of Pluristem only, and are subject to a number
of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

This research has been funded in whole or in part with Federal funds from the
NIAID, NIH, under Contract No HHSN272201000046C.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.